Eltrombopag, low-dose rituximab, and dexamethasone combination as frontline treatment of newly diagnosed immune thrombocytopaenia.
Guillermo José Ruiz ArgüellesPerla R Colunga-PedrazaAndrés Gómez-De LeónCésar H Gutiérrez-AguirreOlga G Cantú-RodríguezJosé C Jaime-PérezPublished in: British journal of haematology (2017)